drugset / Trial / NCT04511416
Preventing Cognitive Decline with Metformin
Phase 3
Active not recruiting
242 enrolled
Garvan Institute of Medical Research
National Health and Medical Research Council, Australia · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.
Timeline
- Start
- 2022-07-15
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metformin | Small molecule | 2000 mg | — |